The PTH receptor type 1 (PTHR1) mediates the actions of two endogenous polypeptide ligands, PTH and PTHrP, and thereby plays key roles in bone biology. Based on its capacity to stimulate bone formation, the peptide fragment PTH (1-34) is currently in use as therapy for osteoporosis. Abaloparatide (ABL) is a novel synthetic analog of human PTHrP (1-34) that holds promise as a new osteoporosis therapy, as studies in animals suggest that it can stimulate bone formation with less of the accompanying bone resorption and hypercalcemic effects that can occur with PTH (1-34 T he parathyroid hormone receptor type 1 (PTHR1) plays a key role in bone biology by mediating the actions of two distinct endogenous polypeptide ligands, PTH, an endocrine hormone that controls daily blood calcium levels, and PTH-related protein (PTHrP), a paracrine-acting morphogenic factor that regulates cell proliferation and differentiation programs in developing bone and other tissues. The receptor is a recognized target for osteoporosis drug therapy, but so far PTH (1-34) is the only approved PTHR1-based therapy in use for this disease (1).
prolonged signaling responses in cells and prolonged calcemic responses in animals, whereas selective binding to RG results in more transient responses. As intermittent PTH ligand action is known to favor the bone-formation response, whereas continuous ligand action favors the net bone-resorption/calcemic response, we hypothesized that ABL binds more selectively to the RG vs the R 0 PTHR1 conformation than does PTH (1-34), and thus induces more transient signaling responses in cells. We show that ABL indeed binds with greater selectivity to the RG conformation than does PTH (1-34), and as a result of this RG bias, ABL mediates more transient cAMP responses in PTHR1-expressing cells. The findings provide a plausible mechanism (ie, transient signaling via RG-selective binding) that can help account for the favorable anabolic effects that ABL has on bone. T he parathyroid hormone receptor type 1 (PTHR1) plays a key role in bone biology by mediating the actions of two distinct endogenous polypeptide ligands, PTH, an endocrine hormone that controls daily blood calcium levels, and PTH-related protein (PTHrP), a paracrine-acting morphogenic factor that regulates cell proliferation and differentiation programs in developing bone and other tissues. The receptor is a recognized target for osteoporosis drug therapy, but so far PTH (1-34) is the only approved PTHR1-based therapy in use for this disease (1) .
Abaloparatide (ABL), known previously as BA058, is a novel synthetic analog of human PTHrP (1-34) that is currently being assessed as a new treatment for osteoporosis (2) . ABL was selected for such therapy based on preclinical trials that suggested a capacity to stimulate bone formation with a reduced amount of bone resorption and accompanying hypercalcemia compared with that observed with PTH (1-34) (3, 4) . The molecular and cellular mechanisms by which PTH ligands modulate processes of bone formation and bone resorption are not completely understood but are known to involve direct effects on osteoblasts coupled with indirect effects, via the RANK-Ligand/RANK signaling pathway, on osteoclasts (5) . One parameter that plays a key role in determining whether treatment with a PTH ligand results in a net anabolic or a net catabolic effect on bone is the timing (ie, frequency and duration) of ligand exposure (6) . Thus, intermittent exposure, as achieved by daily sc injection of the ligand, favors a net bone-formation response, whereas continuous exposure, as achieved by ligand infusion, favors a net bone-resorption response. Typically, anabolic protocols involve daily injection of a PTH peptide at a dose low enough (20 g/d of PTH is used in humans) such that the peptide is fully cleared from the circulation between doses and intervals of pharmacological quiescence (ie, in which blood calcium levels have returned to baseline) are achieved.
Recent studies suggest that structurally distinct peptide ligand analogs for the PTHR1, a class B GPCR, can bind to distinct high-affinity receptor conformations and thereby induce signaling responses that differ markedly in duration. Thus, responses of prolonged duration are observed with ligands that can bind efficiently to a G proteinindependent high-affinity conformation, called R 0 , for which binding is insensitive to GTP␥S, a guanine nucleotide analog that dissociates receptor-G protein complexes, whereas responses of shorter duration are observed for ligands that bind more selectively to a G protein-dependent (GTP␥S-sensitive) receptor conformation, called RG (7) (8) (9) (10) . The prolonged signaling responses observed with R 0 -selective ligands, such as with the particularly long-acting PTH/PTHrP hybrid peptide analog, LA-PTH, presumably arise from a capacity of the ligands to remain associated with the receptor through multiple rounds of G protein activation (and R 0 7 RG isomerization); whereas the more transient responses observed with RG-selective ligands, such as PTHrP and the modified fragment analog, M-PTH (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , result from a more rapid dissociation of the ligand-receptor complex upon G protein activation (10 -12) . When injected into animals, highly R 0 -selective ligands such as LA-PTH induce calcemic responses that persist for several hours longer than that induced by PTH (1-34), without exhibiting a longer half-life in the circulation (11, 12) . Given that a PTH ligand that only transiently activates the PTH receptor could be predicted to induce a more favorable net-bone-anabolic response in vivo than would a ligand that induces more extended signaling responses, we hypothesized that the marked capacity of ABL, compared with PTH (1-34), to stimulate such a net-bone formation response could be attributed, at least in part, to a greater selectivity of binding to the RG vs R 0 PTHR1. We tested this hypothesis by assessing binding of ABL at the two PTHR1 conformations. We also examined the duration of the cAMP signaling response induced by the ligand after initial binding. The results are indeed supportive of a selective bias of ABL for binding to the RG PTHR1 conformation.
Materials and Methods

Peptides
All peptides used were based on the human PTH or PTHrP amino acid peptide sequence, except for the PTH (1-34) analog used for radiolabeling, which was based on the rat PTH sequence, and contained a C-terminal amide, except for LA-PTH, which contained a C-terminal carboxyl group. Specific analogs assessed for function were PTH (1-34) -15) and were prepared by chloramine-T-based radioiodination followed by reversed-phase HPLC purification to obtain a tracer-specific activity of 2200 Ci/mmole.
Cell culture
GP-2.3 cells, an HEK-293-derived cell line that stably expresses the luciferase-based pGlosensor-22F (glosensor) cAMP reporter plasmid (Promega Corp) along with the human PTHR1 (13), were cultured in DMEM supplemented with fetal bovine serum (10%). Cells were seeded into 10-cm dishes for membrane preparations or into 96-well plates for glosensor cAMP assays, and used for assay 2-4 days after the monolayer became confluent.
Cell membrane preparation
Cell membranes were prepared from GP-2.3 cells as described (9) . The confluent cells in 10-cm dishes were washed with hypoosmotic lysis buffer (10mM Tris-HCl, pH 7.8, 4mM EDTA) and collected using teflon in 3 mL of the same buffer supplemented with a protease inhibitor cocktail (1mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, 0.8M aprotonin, 20M leupeptin, 40M bestatin, 15M pepstatin A, 14M E-64; Sigma-Aldrich). The cells were then disrupted by passing 10 -12 times through a steel ball-bearing/cylinder-based cell-shearing device (HGM Industries) affixed at each end to a 10-mL syringe. The nuclei and cell fragments were removed by centrifugation at 800 ϫ g for 10 minutes at 4°C; the membranes in the supernatants were collected by centrifugation at 14 000 ϫ g for 30 minutes at 4°C, and the pellets were resuspended in 0.125 mL of membrane buffer (20mM HEPES pH 7.4, 0.1M NaCl, 3mM MgSO4, 20% glycerol), and the same protease inhibitor cocktail described above. The resulting preparations from multiple 10-cm dishes were pooled and assessed for total protein concentration using the BCA protein detection system (Pierce) and BSA as a standard. Membrane aliquots (0.25 mL) were stored at Ϫ80°C.
Binding to R 0 and RG
Binding to the G protein-independent, R 0 , and G proteindependent RG conformations of the PTHR1 was assessed by competition methods using membranes prepared from GP-2.3 cells as described (9) . The R 0 binding reactions used 125 I-PTH (1-34) as tracer radioligand and contained a high concentration (10M) of GTP␥S to promote uncoupling of the receptor from G proteins; RG reactions used 125 I-M-PTH (1-15) as tracer radioligand and were performed in the absence of GTP␥S. The conformational selectivity of these two assays formats is indicated by the relatively small effect that GTP␥S has on the binding of 125 I-PTH (1-34) vs the much stronger negative effect that it has on binding of 125 I-M-PTH (1-15); these differences in GTP␥S sensitivity are thought to be due, at least in part, to the differences in the modes of receptor interaction used by the two radioligands. Thus, PTH (1-34) interacts with both the N-terminal and regions of the PTHR1, and can bind detectably in the absence of G protein coupling, whereas 125 I-M-PTH (1-15) interacts only with the region of the PTHR1 and thus binds detectably only to receptors in the G protein-coupled RG conformation (9) . Note that in the absence of GTP␥S, 125 I-PTH (1-34) binds to at least two high-affinity states (G protein coupled and uncoupled) such that binding curves obtained under these conditions are biphasic and thus more complex than those obtained for this radioligand in the presence of GTP␥S (7). The binding reactions were performed in 96-well plates at a total volume of 230 L. To minimize nonspecific binding of 125 I-PTH (1-34), R 0 reactions were assembled and incubated in Falcon polystyrene microtiter plates and then transferred at the end of the incubation to a 96-well vacuum filtration plate (MultiScreen filter plates with 0.65M Durapore HV filter membranes, Millipore Corp), in which reactions were terminated by vacuum filtration. RG reactions were assembled and incubated directly in the vacuum filtration plates. Reactions were comprised of membrane assay buffer (20mM HEPES pH 7.4, 0.1M NaCl, 3mM MgSO 4 , 20% glycerol, 3 mg/mL BSA); a protease inhibitor cocktail (see Membrane Preparation), radioactive tracer ligand (150 000 cpm/mL), and cell membranes (membrane protein concentrations were 25 g/mL and 80 g/mL for R 0 and RG assays, respectively), which were added last to start the reactions. Reactions were incubated at room temperature for 90 minutes and then terminated by vacuum filtration followed by two rinses of the filters with membrane assay buffer. The filters were then detached from the plate and counted for gamma irradiation. Nonspecific binding was determined in reactions containing an excess (5 ϫ 10 Ϫ7 M) of unlabeled M-PTH (1-15) or PTH (1-34). The specifically bound radioactivity was calculated as a percent of the radioactivity specifically bound in the absence of competing ligand and then plotted vs ligand concentration using a four-parameter sigmoidal dose-response equation for curve fitting.
cAMP signaling
Ligand effects on PTHR1 mediated cAMP signaling were assessed via the glosensor cAMP reporter expressed in GP-2.3 cells. The intact cells in 96-well plates were preloaded with luciferin for 20 minutes at room temperature; then treated with media alone (vehicle) or media containing a test ligand, and the plates were then placed into a PerkinElmer Envision plate reader, and the development of cAMP-dependent luminescence in each well was measured at 2-minute intervals for time periods of up to several hours. For ligand dose-response experiments, the peak luminescence signals recorded (typically occurring 10 -15 min after ligand addition) were plotted vs ligand concentration. For dynamic wash-out experiments, the cells preloaded with luciferin were treated with media (vehicle) or test ligand (1 ϫ 10 Ϫ9 M) and the development of cAMP-dependent luminescence was measured for 14 minutes ("ligand-on" phase); the plates were then removed from the plate reader, the cells were rinsed twice to remove unbound ligand, treated with fresh media containing luciferin, and luminescence was again recorded for an additional 150 minutes ("wash-out" phase).
ERK-1/2 signaling
Ligand effects on PTHR1-mediated signaling via the ERK-1/2 pathway were assessed in GP-2.3 cells. Intact cells in 96-well plates were treated with media alone (vehicle) or media containing a test ligand, and the plates were incubated at room temperature for 15 minutes. The cells were then rinsed and lysed and the lysates were analyzed for phosphorylated ERK-1/2 proteins using the antibody-based PerkinElmer SureFire assay system.
Data calculations
Data were processed using Excel 2008 (Microsoft Corp) and Prism 5.0 (GraphPad Software, Inc). Aggregate data are expressed as means Ϯ SEM. Curves were fit to dose-response data using a four-parameter, nonlinear regression function. Statistical analyses were performed using the Student t test (two-tailed, unequal variances), significance was inferred from P Ͻ .05.
Results
Binding of ABL and PTH analogs to the RG and R 0 conformations of the PTHR1
The capacities of ABL to bind to the R 0 and RG conformations of the PTHR1 were assessed by radioligand competition methods in reactions performed using membranes prepared from GP-2.3 cells (HEK-293-derived cells stably expressing the hPTHR1). Binding to R 0 was assessed using 125 I-PTH (1-34) as a tracer radioligand and the reactions contained an excess (10M) of GTP␥S, which enriches for the G protein-uncoupled receptor conformation. Binding to RG was assessed in the absence of GTP␥S and using 125 I-M-PTH (1-15) as a tracer radioligand, which binds preferentially to the G protein-coupled conformation of the PTHR1 (9, 10). As control unlabeled peptide ligands we used PTH (1-34), PTHrP (1-36), and the long-acting PTH/PTHrP hybrid analog LA-PTH. Figure 1 shows a schematic of the different analogs assessed in these studies, as well as a structural model of the PTHR1-ECD in complex with the PTHrP (13-34) segment, as determined by x-ray crystalography (14) , with the corresponding 13-34 segment of ABL graphically, superimposed. Figure 2 shows the results of competition binding assays performed to assess binding of these ligands to the intact PTHR1 in either the RG or R 0 confordoi: 10.1210/en.2015-1726 press.endocrine.org/journal/endomation. At the RG conformation, each ligand bound with a similar and high apparent affinity (IC 50 ϳ0.3nM), and although ABL tended to show the highest affinity for RG, the differences vs the other analogs tested were not significant ( Figure 2A and Table 1 ). At the R 0 conformation, a considerably wider distribution of affinities was observed, and the weakest binding ligand was ABL, as it bound to R 0 with an apparent affinity that was approximately 9-fold weaker than that observed for PTHrP , approximately 80-fold weaker than that observed for PTH (1-34), and nearly 400-fold weaker than that observed for LA-PTH ( Figure 2B and Table 1 ). ABL thus exhibited the greatest selectivity for the RG vs R 0 conformation as the affinities at the two respective conformations differed by 1600-fold for ABL (IC 50 s ϭ 0.20 vs 316nM), 110-fold for PTHrP (1-36) (0.32 vs 35nM), 12-fold for PTH (1-34) (0.33 vs 3.9nM) and 2.2-fold for LA-PTH (0.38 vs 0.83nM). This conformational selectivity profile observed for ABL is markedly different from that observed for LA-PTH, as the latter ligand exhibited strong R 0 selectivity, as noted previously (11), and even that for PTHrP (1-36), which was previously identified as a moderately RG-selective ligand (10) .
cAMP signaling potency of ABL and PTH analogs in PTHR1-expressing cells
The capacity of ABL to bind to the RG, G proteincoupled conformation of the PTHR1 with an affinity at least as high as that PTH (1-34) and the other control ligands predicts that the analog will be at least as potent for inducing G protein-mediated signaling responses at the PTHR1. This prediction was borne out by the results of cAMP ligand dose-response assays performed in GP-2.3 cells, which stably express the PTHR1 along with the luciferase-based glosensor cAMP reporter (13) . Thus, the potency of ABL was found to be approximately 5-fold greater than that of PTH (1-34) (EC 50 ϭ ϳ0.087 vs ϳ0.44nM; P ϭ .0009) and similarly several-fold greater than that of PTHrP (1-36) and LA-PTH ( Figure 3 and Table 2 ).
Duration of cAMP-signaling responses induced by ABL and PTH analogs in cells
It has previously been shown that the relative potencies with which different PTH ligands activate cAMP signaling gold), superimposed with the 13-34 region ABL (magenta with side chains of substituted residues: F22E, F23L, H25E, H26K, I28L, E30K, and I31L in atomic CPK colors; the A29Aib substitution is not depicted). The model is derived from the crystal structure of the PTHR1-ECD•PTHrP (13-34) complex (14) . The enlargement of the boxed area identifies five of the PTHrP residues substituted in ABL.
via the PTHR1 correlate with the relative affinities with which the ligands bind to the RG conformation, whereas the durations of the cAMP signaling responses induced by such ligands correlate better with the relative affinities with which the ligands bind to the R 0 conformation (12) . The results of the RG binding and cAMP potency studies shown in Figures 2A and 3 are consistent with such a correlation between RG binding affinity and cAMP signaling potency. To assess the duration of cAMP signaling for ABL and the control peptides, we performed dynamic cAMP wash-out experiments in which we measured the time-course of cAMP production after initial ligand binding and subsequent removal (wash-out) of unbound ligand. Figure 4A shows the time-courses of cAMP development in GP-2.3 cells during the initial "ligand-on" phase of the experiment. Each ligand was added at a concentration that approximated the respective EC 50 (potency) value obtained for that ligand such that the maximum cAMP luminescence responses attained at the end of the ligand-on phase were similar for the different ligands. Figure 4B shows the residual cAMP signaling activity occurring in the same cells after rinsing to remove unbound ligand (note that the increase in luminescence that occurs at the start of this wash-out phase is due to the uptake by the cells of fresh luciferin provided by the media used for the wash-out phase). The residual cAMP signal observed for ABL during the 150-minute duration of the wash-out period was cumulatively 2-fold less than that observed for PTH as shown by the differences in the corresponding area under the curve values derived from these two response curves (4298 Ϯ 561 vs 8664 Ϯ 1698, respectively; P ϭ .05; Table 3 ). The residual response observed for ABL tended to be even less than that observed for PTHrP (1-36) although the difference was not significant. As expected, LA-PTH mediated a much longer response after wash-out than did any of the other ligands tested. These results provide further support for the notion that the duration of cAMP signaling induced by a given ligand at the PTHR1 correlates with the affinity with which that ligand binds to the R 0 receptor conformation. Moreover, they provide data to suggest that the cAMP signaling responses induced by ABL are relatively transient in duration compared with those induced by a similarly efficacious, as measured at the time of the peak response, concentration of PTH (1-34), or, more strikingly, by a highly R 0 -selective ligand such as LA-PTH.
Ligand effects on signaling via the ERK-1/2 pathway in PTHR1-expressing cells
The capacity of ABL and control ligands to activate ERK-1/2 signaling was assessed in GP-2.3 cells. Each ligand, at 5 minutes after being added to the cells (15) induced an increase in ERK-1/2 phosphorylation, as assessed using an antibody-based plate-reader assay, and no (1-36) , or LA-PTH, and luminescence was assessed. At each ligand dose, the peak luminescence response, which typically occurred 10 -15 minutes after ligand addition (luminescence was assessed at 2-min intervals for ϳ60 min), was plotted vs ligand concentration. Data are means (Ϯ SEM) of five or four (LA-PTH) experiments, each performed in duplicate. Curve fitting parameters are reported in Table 2 . press.endocrine.org/journal/endodifference in the potencies of these responses could be detected ( Figure 5 ).
Discussion
The hypothesis tested here was that ABL compared with PTH (1-34) binds with relatively greater selectivity to the RG of the PTHR1 vs the R 0 conformation and thus mediates more transient cell signaling responses. This hypothesis was based on results of studies in animals (3, 4) and in humans (2), which suggest that daily injection of ABL is more effective at inducing net bone-anabolic responses in vivo than is daily injection of PTH (1-34), as such a favoring of bone-formation vs bone-resorption/calcemic effects is associated with intermittent as opposed to continuous PTH ligand exposure.
We found that ABL indeed exhibited greater selectivity for the RG receptor conformation than did PTH (1-34). ABL thus bound to RG with an affinity similar to that of PTH (1-34) while it bound to R 0 with a considerably lower affinity. The high RG selectivity (lower R 0 affinity) observed for ABL was associated with more transient cAMP signaling responses compared with the responses induced by PTH. The effect was especially dramatic when compared with the responses induced by the long-acting analog, LA-PTH, which binds with particularly high affinity to the R 0 conformation (11) . The findings are thus consistent with our hypothesis that the more favorable effects on bone metabolism seen with ABL compared with PTH (1-34) in preclinical and clinical studies arise, at least in part, from a more selective binding of the analog to the RG PTHR1 conformation. The transient signaling actions of ABL were revealed by the use of the glosensor reporter construct, which permit dynamic analyses of intracellular cAMP production both during the initial ligand-binding phase, as well during a subsequent wash-out phase in which unbound excess ligand removed. Analysis of the latter wash-out phase thus revealed that the response durations differed for the different ligands tested, and especially for ABL and LA-PTH. Of note, in our dose-response assays in which the intracellular cAMP levels were measured at a single peak time point attained during the ligand-binding phase, ABL was found to be, if anything, several-fold more potent than each other ligand, including LA-PTH. Thus, the shorter duration of action observed for ABL cannot be explained simply by a weaker potency at the PTHR1. Instead, more easily explained by the differing capacities of the ligands to Table 3 . ) were derived from curve fitting dose-response data; the luminescence observed in vehicle-treated cells was 1.7 Ϯ 0.1 cpsx10 -3. Data are means of five or four (LA-PTH) experiments, each performed in duplicate; P vs PTH (1-34).
bind to the RG vs R 0 conformation, the latter conformation having the capacity to mediate prolonged signaling responses by maintaining a ligand-bound state through multiple rounds of G protein coupling and activation (9, 12) . In contrast, selective binding to the RG conformation is presumed to result in the release of the bound ligand soon after the initial G protein-coupling/activation event, such that signaling terminates shortly thereafter. Other recent studies suggest that different PTH and PTHrP ligands might follow different paths of internalization and that certain longer-acting, R 0 -selective analogs can signal via the G␣ S -cAMP pathway for some time after transiting into the internalized endosomal domain (16 -18) . Moreover, recent data suggest that the capacity of a PTH ligand to mediate persistent cAMP signaling from within endosomes may be regulated, in part, by the level of resistance that the complexes formed between that ligand and the receptor have to endosomal acidification, which occurs in progressive fashion during endosome maturation (19) . It is presently unknown how the signaling actions of ABL are regulated by such internalization processes.
That the PTHR1 has the capacity to mediate signaling responses that differ rather substantially in duration, depending on the structural properties of the ligand and the affinity with which they bind to the R 0 vs RG conformation can be viewed as a type of biased agonism. The concept of biased agonism has now been well established, largely from studies on class A GPCRs that can switch between G protein-mediated cAMP signaling and ␤-arrestin-mediated ERK-1/2 signaling, depending on the particular ligand used and the receptor conformation stabilized (20 -22) . For the PTHR1, certain PTH (7-34) antagonist analogs have been reported to exhibit some biased signaling via the ERK-1/2 pathway (23, 24) . In contrast, a separate study of a panel of PTH and PTHrP agonist and antagonist analogs found, using different assay methods, including the Surefire ERK-1/2 assay used here, no evidence for ERK-1/2-based biased signaling (25) . We also did not detect evidence of qualitative differences in modes of signaling for ABL, as well as for the other ligands tested: PTH (1-34), PTHrP (1-36) and LA-PTH. Thus, each ligand potently activated both the cAMP and ERK-1/2 pathways. Rather, ABL, exhibited properties of biased agonism that were based on inducing signaling responses that differ in overall duration, compared with those induced by structurally distinct ligands, including PTH (1-34) and especially LA-PTH.
The molecular mechanisms by which ABL or any PTH or PTHrP ligand effectively binds to and stabilizes a particular receptor conformation and thus activates one type of intracellular signaling response vs another are largely unknown. Ligand binding to the PTHR1 involves two main components of bimolecular interaction: one between the C-terminal (15-34) helical domain of the ligand and the ECD portion of the receptor, and the other between the N-terminal (1-14) portion of the ligand and the trans- press.endocrine.org/journal/endomembrane domain/extracellular loop region of the receptor (26) . Whereas the ECD component provides overall binding affinity, the TMD component mediates the activation events necessary for signal transduction. Crystalographic studies on the isolated ECD domain of the PTHR1 in complex with the approximate (15-34) portions of either PTH or PTHrP show that the two ligands bind in similar fashion, such that each fits as an amphipathic ␣-helix into a groove that runs along the central core of the ECD, with ligand residues aligning with Trp23, Leu24, and Leu28 in PTH making strong hydrophobic interactions with complementary surfaces in the receptor (14) . One difference observed in the binding used by the PTH and PTHrP domains, however, is that there is a slight bend in the PTHrP helix at about residue 17, such that the 17-34 portions of the two helices diverge slightly in their position in the binding pocket and contact sites used (14) . ABL emerged from a peptide design effort aimed at stabilizing this C-terminal helix portion of PTHrP (1-34) (27) , and thus contains eight modifications, including a conformationally constraining Aib at position 29 could be expected to alter at least some of the interactions that occur within this core ECD binding pocket. How these substitutions specifically affect the overall receptor-binding process and thus lead to distinct signaling modes in cells and biological outcomes in vivo remains to be determined. In any event, the current findings with ABL, compared, for example, with those with LA-PTH (11), seem consistent with the emerging concept that variations in the residence times with which structurally distinct ligands bind to a given receptor, due to alterations in specific modes of ligand-receptor contact, can lead to important differences in functional effects obtained for those ligands in cells and intact organisms (28) . The current data support the notion that ligand-dependent receptor conformational selectivity can occur at the PTHR1 and, moreover, can have relevance in vivo, as suggested by the recent clinical trial results of ABL (2) . In particular, they show that modulating, eg, via side-chain modification, a PTH or PTHrP ligand's selectivity for the R 0 vs RG state can be a way to alter the duration of action of that ligand in target cells, which, for PTH ligand-induced bone, seems to be a key determinant of biological outcome.
